PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

• Status: Recruiting
• Trial end date: 2023-03-30

Summary

The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Plexxikon
• Treatments: Abiraterone Acetate; Olaparib; Prednisone